Ridgetech's Jiuxin Medicine Elected Vice-President of Hangzhou Biomedical Association

Ridgetech, Inc., a wholesale distributor of pharmaceutical products in China, announced that its subsidiary, Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine"), has been elected as a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association. The association is scheduled to be officially inaugurated on July 24, 2026. This appointment acknowledges Jiuxin Medicine's role in enhancing pharmaceutical supply chain transparency and its implementation of full-variety drug traceability code scanning across Zhejiang Province.

The association aims to promote the high-quality development of the regional biomedical sector. In March 2026, officials from the Zhejiang Medical Products Administration inspected Jiuxin Medicine, recognizing its progress in implementing the drug traceability initiative.

Operating under Ridgetech's dual-engine strategy, Jiuxin Medicine focuses on B2B pharmaceutical distribution and supply chain solutions. The company utilizes AI-enabled technologies and big-data analytics in conjunction with its drug traceability code system to improve real-time visibility and traceability of pharmaceutical products throughout the distribution process.

Zhejiang Province is a leading region in China's national drug traceability reform, which mandates the recording and tracking of pharmaceutical products throughout their lifecycle. Since January 1, 2026, designated healthcare providers have been required to upload full traceability data.

"We are truly honored that Jiuxin Medicine has been elected as a vice-president unit of the Association," said Frank Zhao, Interim CEO and CFO of Ridgetech. "This recognition is a testament to our achievements to date and a meaningful call to action for our future endeavors. We are committed to remaining at the forefront of compliance, innovation, and operational excellence."